bristol-my squibb compani bm engag discoveri develop licens manufactur market distribut
sale pharmaceut nutrit product compani two segment pharmaceut nutrit
pharmaceut segment made global pharmaceut intern consum medicin busi nutrit
segment consist mead johnson nutrit mead johnson primarili infant formula children nutrit busi
januari compani complet divestitur bristol-my squibb medic imag medic imag avista capit
partner june bm acquir kosan bioscienc inc develop oncolog product august compani
complet divestitur convatec busi cidron healthcar limit affili nordic capit fund vii
decemb bm complet sale brand busi egypt glaxosmithklin
rank
return equiti
price book
incom statement summari figur billion
global peer group analysi figur usd
merck co
compani
merck co
compani
hi
long-term fundament rank
short-term technic rank
rank number list
pharmaceut compani trade today unit state
market capit billion
pharmaceut compani highest total
asset highest revenu
within sector rel low price-to-earnings moder p/
strong rel roe roa
compani paid dividend last twelv month
dividend yield high
stock score set
involv valuat size
financi perform
rank accord
averag valu
rank lowest
rank
short term rise combin strong volum
result strong momentum rise day
significantli price discount
day move averag price rang
trade discount
high premium low
invest exactli one year ago worth
capit loss dividend reinvest
stock score set
price perform trade
volum rank
accord averag
valu paramet
highest rank
lowest rank
bristol-my squibb compani place bss rank nyse perform past year percentil rank
bristol-my squibb compani new entrant boston consult group list top innov compani rank
rank mcap march pwc top global compani improv year rank
march
largest revenu ft global
rank newsweek corpor knight capit world greenest compani outstand score
product wast product carbon product
largest revenu forb global
new entrant industri week list world largest manufactur revenu rank
sector total bracket
revenu billion aggreg sector revenu
billion previou year
net profit billion aggreg sector net profit
billion previou year
ebit billion aggreg sector ebit
billion previou year
mcap billion aggreg sector mcap
billion previou year
earn yield time bond yield
last trade session net rise
stock advanc twelv time biggest
one day rise may
price-to-earnings versu sector averag
market averag estim share trade
current year price-to-earnings forward year price-to-earnings
rel yield stock defin yield
divid averag yield dividend yield stock
suggest stock
under-valued dividend yield term
return equiti versu sector averag
market averag
total liabilities/ebitda less compar
favour joseph piotroski benchmark
return asset versu sector averag
market averag
return capit employ versu sector averag
market averag
net profit margin averag last year
consid superior suggest high margin safeti
per du pont analysi return equiti high
comput net profit margin time
asset turnov sales/asset time leverag factor
total assets/sharehold equiti
improv last year
also follow criteria set benjamin graham
earnings-to-pric yield least twice triple-a bond
stock earn yield time triple-a bond
yield
dividend yield least two-third triple-a bond yield
stock dividend yield time triple-a bond yield
total debt equal less twice net quick liquid
valu total debt billion time net
liquid valu billion
earn growth recent ten year
compound doubl earn five-year
period earn per share doubl
trail twelv month price-to-earnings cyclic
adjust price earn cape cape
develop economist robert shiller base methodolog
benjamin graham david dodd smooth earn
across period base move averag
dividend yield time triple-a bond yield
benchmark set benjamin
growth quarterli revenu net incom
previou correspond period pcp quarterli revenu
million million
previou correspond period pcp quarterli net profit
million million
ebit margin posit increas
past year
turnov quarter
return equiti
return asset
price premium volum
weight averag price past year
premium greater suggest
topish level cautiou buy current price
fall rise last three month number fall
outnumb rise
nyse market stock unit trade
today stock rel strength
indic trail market
indic exponenti move averag ema
minu ema neg suggest
price/map lower
price/map
price map ratio bearish indic
past day ratio time
suggest downsid map
lower map bearish indic
map decreas decreas
price risen upper bolling band
stock also overbought accord
 indic
stock score mere set
return asset improv improv
asset turnov growth revenu exceed growth
asset
price/sal versu sector averag market
averag estim share trade
current year price/sal forward year price/sal
price book higher averag
total nyse market estim share trade
current year price book forward year price
book
 ratio defin jame tobin mcap divid
total asset compar rest market
stock overvalu rank bottom stock
valu ratio
averag annual compound return share price
last year under-perform averag
annual compound return
earn yield less benchmark yield
price book valu
volum index average
stock trade low high
averag daili volatil place stock
quartil market mean mildli volatil
result report
us million except per share data share outstand
allianc revenu
product sold
market sell administr
research develop
provis incom tax
net earn attribut bm
cash equival
prepaid expens
properti plant equip
pension liabil
commit conting
capit excess par valu stock
accumul comprehens loss
less cost treasuri stock
total liabil equiti
adjust reconcil net earn net cash provid
depreci amort net
pension settlement amort
divestitur gain royalti
chang oper asset liabil
net provid oper activ
sale matur market secur
purchas market secur
divestitur proce
acquisit payment
net provid by/ use invest activ
repay long-term debt
repurchas common stock
net use financ activ
effect exchang rate equival
net increase/ decreas equival
equival begin period
equival end period
quarterli report sequenti growth
quarterli report report sequenti rise quarterli net profit
nyse announc net profit quarter-end march previou
quarter year-earli period
sequenti growth ep
sequenti growth revenu
sequenti growth net profit
compar previou correspond period pcp year-over-year ep revenu
net profit
pcp growth ep
pcp growth revenu
pcp growth net profit
result report annual
us million except per share data share outstand
allianc revenu
product sold
market sell administr
research develop
provis incom tax
net earn attribut bm
cash equival
prepaid expens
properti plant equip
pension liabil
author million share issu outstand
liquid valu per share
common stock par valu per share author billion
share billion issu
capit excess par valu stock
accumul comprehens loss
less cost treasuri stock million common share
million common share
total liabil equiti
adjust reconcil net earn net cash provid
depreci amort net
pension settlement amort
divestitur gain royalti
loss/ gain equiti invest
chang oper asset liabil
net provid oper activ
sale matur market secur
purchas market secur
divestitur proce
acquisit payment
net use /provid invest activ
issuanc long-term debt
repay long-term debt
repurchas common stock
net use financ activ
effect exchang rate equival
increas equival
equival begin year
equival end year
earn cont op margin
annual report bristol myer squibb net profit
nyse report net profit year-end decemb
previou year
major chang compar previou year
total revenu
ebit margin
ebit total asset
good sold sale
profit tax sale
sale market expens sale
debt equiti
total liabil total asset
work capit total asset
retain earn total asset
total current asset total asset
net tangibl asset per share
total non-curr asset total asset
current debtor total asset
fix asset total asset
total revenu total asset steadi
tax expens sale
current ratio steadi
intang total asset
fig year-on-year comparison per share figur
fig year-on-year comparison perform ratio
total debt net tangibl asset
total liabil ebitda
total liabil oper
current ratio
common size ratio asset
total non-curr asset total asset
total current asset total asset
intang total asset
current debtor total asset
fix asset total asset
common size ratio sale
good sold sale
profit tax sale
sale market expens sale
tax expens sale
fig five-year record growth perform
last year total revenu averag ebitda averag net profit averag compound annual
growth rate compound-annual-growth-rate averag total revenu net profit ebitda
fig five-year record ebitda oper profit net profit roe roa roce
net profit margin average figur
return equiti
return asset
return capit employ
profit tax
oper cash flow
sale
past year incom tax profit tax increas
acquisit bristol-my squibb
announc stockhold vote approv
compani propos combin bristol-my squibb
compani nyse approxim vote cast
share outstand entitl vote
vote favor transact special meet
behalf celgen board director would like
thank stockhold overwhelm support
transact said mark all chairman chief execut
offic celgen
detail click
march independ proxi advisori firm iss glass
propos merger celgen
independ proxi advisori firm iss glass lewi
propos merger celgen bristol-my squibb urg
sharehold vote merger-rel propos
white proxi card today
today announc independ proxi advisori firm
institut sharehold servic iss glass lewi co
detail click
march bristol-my squibb issu statement
celgen settlement alvogen revlimid patent
today issu follow statement regard celgen
celg settlement lotu pharmaceut co ltd
alvogen pine brook llc collect alvogen relat
patent revlimid
pleas celgen reach settlement
alvogen relat patent revlimid
detail click
base issu equiti share market
capitalis billion nyse largest
compani total revenu
march bristol-my squibb board director send
letter sharehold highlight compel strateg
financi rational celgen transact
urg sharehold vote propos transact
white proxi card
board director today sent open letter compani
sharehold regard previous announc definit
merger agreement celgen corpor celg
detail click
today announc quarterli dividend
per share ex dividend date thursday april
record date friday april payabl
transact track close third quarter
today announc sharehold vote approv
issuanc share bristol-my squibb common stock
connect compani pend merger celgen
corpor celg special meet
pleas outcom today special meet
thank sharehold support combin
said giovanni caforio chairman chief execut
offic bristol-my squibb
detail click
today report result first quarter
highlight strong demand opdivo nivolumab eliqui
apixaban robust oper perform across
good first quarter compani
remain focus deliv strong sale growth
priorit brand continu advanc scienc
diseas area focu said giovanni caforio chairman
chief execut offic bristol-my squibb
detail click
earli particip exchang offer consent
solicit celgen corpor note
bristol-my squibb announc today requisit
number consent receiv adopt propos
amend respect outstand note celgen
corpor celg celgen result base
earli tender offer exchang exchang
offer outstand note celgen note
issu celgen aggreg princip
amount new note issu bristol-my squibb
bristol-my squibb note cash ii relat consent
solicit consent solicit made bristol-
myer squibb behalf celgen adopt certain propos
amend amend indentur govern
celgen note celgen indentur
celgen execut supplement indentur celgen
indentur contain amend
detail click
privat offer senior unsecur note
bristol-my squibb today announc subject market
condit intend commenc privat offer
offer sell senior unsecur note note
offer conduct connect previous
announc propos acquisit merger celgen
detail click
commenc exchang offer consent
solicit celgen note
bristol-my squibb announc today commenc
connect previous announc acquisit celgen
corpor celg celgen exchang offer
outstand note celgen note issu
celgen aggreg princip amount
new note issu bristol-my squibb bristol-
myer squibb note cash
previous announc bristol-my squibb burgundi
merger sub inc wholli own subsidiari bristol-my
squibb merger sub enter agreement
merger merger agreement celgen
detail click
vero beach fl april mr quinton oswald
entrepreneur three decad experi biotech
big pharma live hour north miami florida
lot advic offer entrepreneur
born south africa obtain educ
began career south africa bristol myer move
holland play central role merg bristol myer
squibb form
detail click
year sustain excel award
recogn bristol-my squibb compani nyse
year sustain excel
award outstand contribut leadership improv
energi effici facil world-wide bristol-my squibb
earn year award
proud commit environment
respons recogn
vice presid environ safeti sustain
detail click
surviv result pool analys opdivo
nivolumab previously-tr non-smal cell lung
result pool analys surviv data four studi
checkmat patient
treat opdivo nivolumab pool analysi
four studi opdivo-tr patient aliv
four year
detail click
relat celgen transact
current report provid certain financi
inform respect celgen corpor celgen
bristol-my squibb spropos acquisit celgen
previous disclos current report file
januari bristol-my squibb burgundymerg sub
inc wholli own subsidiari bristol-my squibb merger
sub enter agreement merger
merger agreement celgen
detail click
jose baselga resign bristol myer squibb
director resign take effect sep
boerner execut vice presid august
appoint christoph boerner
execut vice presid appoint take effect aug
march starboard issu statement bristol-my
affili starboard sharehold bristol-my
squibb compani bristol-my compani
nyse today provid follow statement
invest bristol-my
extrem disappoint conclus reach
proxi vote advisori firm institut sharehold servic
iss glass lewi co llc glass lewi
detail click
march starboard mail letter bristol-my squibb
affili starboard sharehold bristol-my
squibb compani bristol-my compani
nyse today announc mail letter
bristol-my sharehold regard compani propos
merger celgen corpor merger believ
ill-advis best interest bristol-my
letter avail view
starboard valu lp new york-bas invest advis
focus differenti fundament approach invest
primarili publicli trade
detail click
march heat biolog report result provid
surviv benefit patient cold tumor til
baselin least like respond checkpoint inhibitor
preliminari data suggest addit bristol-my
restor respons treatment tumor progress
detail click
march biotechnolog compani rush develop
treatment variou ill found global
new york march -- diseas commonplac
around world especi region access
adequ healthcar underdevelop region diseas
aid malaria tuberculosi ravag countri
inhabit accord world organ
third world countri peopl face ten thousand death
daili due untreat condit mani diseas
occur environment impact pure hereditari
detail click
report buy sell trail month continu
share
report institut buy sell share
hold end quarter
report hold institut decemb
total report hold institut share
report hold institut
issu capit
fig net buying/ sell institut trail month ttm
usd valu
new york mellon corp
state tennesse treasuri
new patent issu us pto
view detail click patent link
imidazopyridazin compound use modul and/or ifn- alpha respons
tricycl sulfon ror gamma modul
fibronectin base scaffold protein improv stabil
modifi relaxin polypeptid compris pharmacokinet enhanc use thereof
optim antibodi bind lymphocyt activ use thereof
cancer immunotherapi disrupt signal
cancer immunotherapi disrupt signal
cancer immunotherapi disrupt signal
stabl subcutan protein formul use thereof
devic method test inspect integr contain
anti-ico agonist antibodi use thereof
fibronectin base scaffold domain protein bind myostatin
treatment waldenstroom macroglobulinemia
thiazolyl- thiadiazolyl-substitut pyridyl compound use kinas inhibitor
method treat cancer administ igf-ir bind molecul
triazolopyridin inhibitor myeloperoxidas
substitut aza benzofuran compound treatment hepat
fc fusion protein compris novel linker arrang
quinazolin potassium ion channel inhibitor
substitut tetrahydroisoquinolin compound factor xia inhibitor
macrocycl factor xia inhibitor
ipilimumab variant enhanc adcc
method treat immun diseas administ antibodi polypeptid specif bind
carbazol compound use bromodomain inhibitor
antibodi tigit
therapeut use modifi polypeptid
compound anti-cancer agent
fuse pyridin kinas inhibitor
quinuclidin compound nicotin acetylcholin receptor ligand
treatment melanoma use antibodi antibodi
antibodi
diamid macrocycl factor xia inhibitor
compound treatment hepat
antibodi bind peptidoglycan recognit protein
method select bind protein
compound use immunomodul
cancer immunotherapi disrupt signal
benzofuran substitut primari benzamid hcv inhibitor
cyclic urea inhibitor rock
benzofuran compound treatment hepat
benzofuran substitut bicycl secondari benzamid hcv inhibitor
lactam inhibitor rock
five-memb heterocycl use serin proteas inhibitor
tricycl compound anti-cancer agent
heterocycl compound use inhibitor tnf
apj agonist
substitut tetrahydrocarbazol carbazol carboxamid compound
process intermedi make tubulysin analog
antibodi use thereof
benzofuran substitut secondari benzamid hcv inhibitor
diamid macrocycl fxia inhibitor
combin antibodi antibodi treat tumor
tubulysin analog method make use
antibodi use thereof
carbamoyloxymethyl triazol cyclohexyl acid lpa antagonist
mammalian cell cultur process protein product
method treat dermatomyos polymyos administ solubl molecul
carbazol compound use bromodomain inhibitor
imidazothiadiazol imidazopyrazin deriv proteas activ receptor inhibitor
treat platelet aggreg
mammalian cell cultur process protein product
heteroaryl substitut pyridyl compound use kinas modul
heteroaryl substitut pyrrolotriazin amin compound inhibitor
carbazol tetrahydrocarbazol compound use inhibitor btk
antibodi use thereof
pyrrolidin modul treatment diseas diabet
amide-substitut heterocycl compound use modul and/or ifn alpha
substitut factor xia inhibitor
method treat express cancer
antibodi use
radioligand imag receptor
alkyl-amide-substitut pyridyl compound use modul and/or ifn alpha
lactam-contain compound deriv thereof factor xa inhibitor
substitut pyridinon inhibitor
enantioselect synthesi pyrroloindol compound
imidazo-pyridazin deriv casein kinas delta inhibitor
furopyridin compound treatment hepat
dihydropyridon factor xia inhibitor
substitut tetrahydroisoquinolin compound factor xia inhibitor
phthalazinon isoquinolinon rock inhibitor
method reduc glycoprotein aggreg
ammonium deriv treatment hepat
crystallin form factor xia inhibitor
cyanoamino aza benzofuran compound treatment hepat
triazolopyridin triazolopyrimidin inhibitor myeloperoxidas
target therapeut base engin protein bind egfr
compound treatment hepat
tricycl pyrido-carboxamid deriv rock inhibitor
composit monoval bind method use
bristol-my squibb compani bm engag discoveri develop licens manufactur market
distribut sale pharmaceut nutrit product compani two segment pharmaceut
nutrit segment made global pharmaceut intern consum
medicin busi nutrit segment consist mead johnson nutrit mead johnson primarili
infant formula children nutrit busi januari compani complet divestitur bristol-
myer squibb medic imag medic imag avista capit partner june bm acquir kosan
bioscienc inc develop oncolog product august compani complet divestitur
convatec busi cidron healthcar limit affili nordic capit fund vii decemb
bm complet sale brand busi egypt glaxosmithklin
board manag creation sharehold valu
board director year sinc appoint
giovanni caforio chief execut offic bristol-
myer squibb sinc may serv
compani board director sinc june may
assum role chairman board
ceo giovanni led compani focu research
develop transform medicin includ
lead portfolio immunotherapi fundament
chang way cancer treat leadership bm
evolv oper model order increas speed
background physician giovanni help
strengthen compani patient-focus cultur -- one driven
innov speed account passion leader
focus busi valu compani cultur
promot reward divers inclus
prior becom ceo giovanni serv chief oper
offic respons lead fulli integr world-wide
commerci organ companywid function
enterpris servic global manufactur suppli
preced work compani chief commerci
giovanni join bristol-my squibb vice presid
gener manag itali world-wide medicin group
assum ad respons greec israel
south east europ appoint
senior vice presid european market brand
commerci reloc us assum
role senior vice presid oncolog
oncolog immunolog becom presid
compani organ prior join bristol-
myer squibb giovanni spent year
number leadership posit
born educ itali giovanni receiv
univers rome
charl bancroft respons compani world-wide
financ oper includ controllership area tax
treasuri audit servic procur strateg initi
global commerci manufactur financ
oper charli also respons busi
develop strategi allow integr approach
financi plan busi develop strategi
support compani effect meet long-term
goal charli join compani kpmg
sinc held posit increas respons within financ
organ includ intern assign
commerci oper respons latin american
east africa canada japan sever countri
pacif rim charli receiv bachelor scienc degre
account drexel univers master busi
administr templ univers
dr vousden age senior group leader
franci crick institut london sinc februari chief
scientist cancer research uk cruk sinc juli
serv director cruk beatson
institut glasgow prior held leadership role
nation cancer institut maryland
dr vousden bring board year
experi lead ground break cancer research
fellow royal societi serv member
scientif advisori board centro nacion de investigacion
oncologica grail inc ludwig institut cancer research
pmv pharma swiss institut
experiment cancer research dr vousden also council
member european molecular biolog organ
mr storch age serv chief execut offic
oper depart store includ sak fifth avenu
outfitt sak kaufhof inno e-commerc
busi gilt novemb januari serv
chairman chief execut offic storch advisor
also serv chairman toy us inc februari
novemb chief execut offic toy us
februari may prior join toy us mr
storch serv vice chairman target corpor join
senior vice presid strategi serv
role increas senior next year prior
join mr storch partner mckinsey compani
director fanat inc
skill experi retail veteran
year experi mr storch provid board valuabl
busi leadership manag insight includ
expertis lead organ global oper give
keen understand issu face multi-national
busi qualiti make valu member
audit committe addit prior servic
compens committe anoth public compani posit
well serv member compens
dr sato age serv chairman board denali
therapeut inc previous serv professor
manag practic harvard busi school juli
juli juli octob serv
professor practic molecular cell biolog
dr sato retir presid vertex pharmaceut
incorpor global biotechnolog compani
respons research develop busi
corpor develop commerci oper legal
financ dr sato also serv chief scientif offic senior
vice presid research develop chair
scientif advisori board vertex name presid
serv chairman inc
board director inc
peer health exchang inc serv co-chair
task forc scienc engin harvard univers
co-chair advisori council lifesci nyc
mr grobstein age retir vice chairman ernst
young llp independ regist public account firm mr
grobstein work ernst young
admit partner
serv vice chairman intern oper
vice chairman plan market
industri servic vice chairman
account audit servic
serv board truste execut committe
treasur central park conserv
also serv board director peer health
mr arduini age presid chief execut
offic integra lifesci hold corpor global
medic technolog compani sinc januari current
serv member integra board director serv
presid chief oper offic integra novemb
januari join integra mr arduini
corpor vice presid presid medic deliveri
baxter healthcar prior join baxter mr
arduini work gener electr healthcar spent
much year varieti manag role
domest global busi culmin lead global
function imag busi mr arduini also serv board
director advam advanc medic technolog
associ board director mdic medic devic
innov consortium board director
skill experi year healthcar
industri mr arduini bring board extens leadership
busi oper experi particularli respect
manufactur sale medic technolog devic
addit mr arduini experi serv public compani
chief execut offic former chief oper offic
posit well serv member audit committe
mr paliw age serv chairman presid
chief execut offic harman intern industri inc
connect technolog compani automot consum
enterpris market sinc juli mr paliw serv
presid chief execut offic harman sinc juli
prior join harman mr paliw serv member
group execut committe abb ltd provid industri
autom power transmiss system servic
januari june
mr paliw also serv presid global market
technolog abb ltd januari june
chairman chief execut offic abb north america
januari june presid chief
execut offic abb autom technolog divis
octob decemb
mr paliw serv board busi advisori council
farmer school busi miami univers
india busi council usibc board director also
member ceo busi roundtabl washington
 india ceo forum
mr laci age former non-execut chairman dave
buster entertain inc previous serv
chairman chief execut offic sear roebuck co
vice chairman chief execut offic
successor sear hold corpor
mr laci also serv vice chairman sear hold
corpor recent mr laci serv
senior advisor oak hill capit partner privat
equiti invest firm
truste fidel fund california chapter
mr laci director center advanc studi
behavior scienc stanford univers
sandi leung serv legal advisor board director
compani execut respons shape
compani legal strategi sandi also respons
secur philanthropi
acceler pace scienc government polici
regul overal global complex across industri
requir us even agil ever say sandi
legal team bring strateg valu across aspect
busi practic sound counsel guid
compani mission help patient
sandi join bristol-my squibb staff attorney
litig depart becam assist counsel
one year later name associ counsel
sandi appoint posit counsel corpor
secretari appoint act gener counsel
name gener counsel sandi
name execut vice presid
prior join compani sandi prosecutor
advic aspir manag posit
good will hard work
bring good excel judgment expertis tabl
import must great person integr
someon peopl trust peopl trust feel
comfort seek advic also respect peopl
superior everyon
sandi earn law degre boston colleg law
bachelor degre tuft univers
dr lynch serv chairman chief execut offic
massachusett gener physician organ member
massachusett gener hospit board sinc
dr lynch director yale cancer center
richard jonathan sackler professor intern
medicin yale cancer center yale school medicin
also serv physician chief smilow cancer hospit
yale-new sinc prior dr lynch
professor medicin harvard medic school chief
hematology/oncolog massachusett gener hospit dr
lynch member american associ cancer
research american societi clinic oncolog
intern associ studi lung cancer
ann powel judg global head human resourc
bristol-my squibb whose mission discov develop
deliv innov medicin help patient prevail
seriou diseas ann direct respons drive
corpor global capabl talent manag cultur
organiz effect tie directli busi
perform ann work across enterpris support bristol-
myer squibb commit creat energ work
experi cultur power divers broadli
inclus individu encourag exceed
potenti inspir make innov contribut
patient global commun live work
courag passion workforc truli inspir
drive even higher level engag make differ
live patient say ann ann industri experi
expertis lie execut compens leadership develop
chang manag diversity/inclus train design
deliveri talent acquisit labor relat merger
acquisit divestitur start-up
mr joseph caldarella senior vice presid corpor
control bristol-my squibb co vice
presid corpor control vice
compani
technolog organ posit compani success
rapidli evolv digit age focus ensur
compani inform asset oper reliabl
access secur drive digit compani
adopt new approach digit health continu
innov approach long-term partnership key servic
excit time lead team advanc
technolog provid new opportun streamlin live
unpreced way includ manag health paul
said deliv digit capabl acceler compani
work bring innov medicin patient
challeng honor
throughout experi domest intern high-
tech consum packag good biopharmaceut
compani paul career focus strateg
leverag inform technolog drive superior perform
join bristol-my squibb paul held posit kraft
gener food hewlett-packard member
research board serv board truste
paul bachelor degre electr engin
master degre comput scienc steven institut
technolog complet program manag
develop harvard busi school program
leadership develop imd switzerland
report report prepar minkabu infonoid inc minkabu analyst opinion project report
suppli global market intellig llc compani profil company-rel inform co-own
minkabu infonoid inc pk clean ltd buysellsign group compani stock index price suppli
stock exchang tradeg exchang euronext deutsch brse ag bme stuttgart stock exchang tradeg exchang
exchang clear limit taiwan stock exchang tokyo stock exchang nagoya stock exchang toronto stock exchang
express opinion analyst sole person opinion author contributor report minkabu
respons accuraci complet reliabl timeli inform opinion respons error
omiss therein assum liabil direct indirect loss damag particular lost profit may
incur result relianc inform use report inform report may contain project
opinion assumpt estim forecast relat futur busi perform event intend exampl
repres predict minkabu current futur perform compani secur
minkabu make warranti regard accuraci reliabl project opinion assumpt estim forecast
liabil damag kind aris relianc inform forward-look statement guarante
futur perform involv risk uncertainti actual result may differ forward-look statement result
variou factor minkabu oblig updat correct inform report constitut recommend
make invest purchas sell specif invest product report intend give financi
invest advic conduct care independ analysi seek advic profession advisor
suitabl invest need minkabu express opinion compani secur invest
product fluctuat futur perform thereof stock price rate comment includ target price buy
sell hold creat aggreg opinion individu investor opinion analyst secur
compani rate overvalu under-valued fairlyvalu fair stock price other display ancillari
rate object fact base statist record minkabu express opinion compani secur
invest product fluctuat futur perform thereof therebi either
minkabu repres warrant report appropri avail view download locat
exclus respons complianc applic local law regul view download report report
intend use inform refer purpos constitut solicit offer make
invest purchas sell specif invest product
minkabu regist broker dealer invest advisor analyst invest banker underwrit minkabu may hold
secur refer report includ deriv instrument may busi relat compani discuss
herein without prior written consent minkabu reproduct copi transmiss transfer distribut public
similar action content report shall made
